Dyne Therapeutics (DYN) Insider Dirk Kersten Sells $941K of Stock

Dirk Kersten Continues Selling Pattern

Insider Dirk Kersten sold 46,901 shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) on June 18, 2026. The transaction brought in a total of $941,303.07, with the shares sold at an average price of $20.07. According to SEC filings, the trade was completed under a pre-arranged Rule 10b5-1 trading plan.

This transaction is part of a larger, recurring sequence of disposals by Kersten. Just a few days later, on June 22, 2026, Kersten sold another 190,676 shares of the company. These scheduled sales allow corporate insiders to trade a predetermined number of shares at set times to avoid any appearance of trading on non-public information.

Dyne Therapeutics Stock Activity

On Tuesday, shares of Dyne Therapeutics closed at $20.87. The biotech company has seen its stock price fluctuate within a 52-week range of $11.92 to $27.30. The stock is currently trading slightly above its 200-day moving average of $19.78, though it remains below its 50-day moving average of $23.85. Dyne Therapeutics currently has a market capitalization of approximately $3.20 billion.

Broad Insider Sales Recorded in June

Several other Dyne Therapeutics insiders were active in the market during the same period. Fellow insider Jason Rhodes conducted multiple planned transactions, selling 147,760 shares on June 23, 2026, 95,900 shares on June 24, 2026, 24,100 shares on June 25, 2026, and 309,268 shares on June 26, 2026. Additionally, Chief Financial Officer Erick Lucera sold 2,362 shares on June 25, 2026, at an average price of $20.37, totaling $48,113.94. Unlike the trades by Rhodes and Kersten, Lucera's transaction was not designated as a planned trade.

Analysts Set New Price Targets

Wall Street researchers keep a close eye on the biotechnology firm, which currently sports a consensus recommendation of strong buy from 15 analyst opinions. The average price target for the stock is $37.2, with a high estimate of $50.0 and a low estimate of $10.0.

On September 30, 2026, Chardan Capital maintained its buy rating on the stock with a price target of $38.0. The same day, HC Wainwright & Co. kept its buy rating but lowered its target price to $32.0. Piper Sandler reiterated an overweight rating on September 29, 2026, with a target of $47.0. Earlier in the month, Morgan Stanley maintained its overweight rating with a target of $36.0, while JP Morgan downgraded the stock to an underweight rating with a target of $10.0 on September 9, 2026.

Focusing on Muscle Diseases

Dyne Therapeutics is a clinical-stage biotechnology business based in Waltham, Massachusetts. The company focuses on discovering and creating therapeutics for serious neuromuscular diseases. It uses its proprietary FORCE platform to design treatments for conditions like myotonic dystrophy type 1, Duchenne muscular dystrophy, and Pompe disease. Because the company is still in the clinical development phase, it is not yet profitable and has negative earnings per share of -$3.26.

What to Watch at Dyne Therapeutics, Inc.

Investors tracking Dyne Therapeutics will want to watch the company's progress with its clinical pipeline and its upcoming quarterly financial results. The company is scheduled to report its next earnings on November 5, 2026. While insider sales can draw attention, they are often planned months in advance and do not necessarily indicate a change in the company's business outlook.